Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 3Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Leukemia, B-Cell 2Lymphoma, B-Cell 1Lymphatic Diseases 1Hematologic Diseases 1Heart Failure 1

Interventions

fludarabine 3Cyclophosphamide 3obinutuzumab 2acalabrutinib 2ricolinostat 1pirtobrutinib 1idelalisib 1ibrutinib 1fludarabine phosphate 1Rituximab 1Mesna 1Leukapheresis 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, B-Cell × acalabrutinib × 30 days × Clear all
NCT05557695 2026-06-02

EPIC

AstraZeneca

Recruiting
350 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡